WellSky, a prominent technology company in health and community care, has announced its acquisition of Bonafide, a software solution designed for durable medical equipment (DME) and home medical equipment (HME) providers. This acquisition enhances WellSky’s presence in the DME/HME sector,…
Modalis Therapeutics Corporation (Tokyo Stock Exchange: 4883, CEO: Haru Morita) has announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to MDL-101, a novel precision medicine for congenital muscular dystrophy type 1A (LAMA2-CMD). Modalis…
Maze Therapeutics, a biopharmaceutical company focused on developing precision medicines using human genetics, has announced positive results from the Phase 1 clinical trial of MZE829 in healthy volunteers. MZE829 is an oral small molecule that inhibits APOL1, which Maze is…
Amid fluctuating market conditions and regulatory changes, pharmacies can leverage automated production to enhance efficiency, boost profitability, and substantially lower operational costs. Pharmacy automation provider JFCRx™ has launched TruCard™, a multi-dose adherence blister card packaging and inspection system designed to…
Agomab Therapeutics NV has announced an $89 million (€82.1 million) Series D financing round, featuring contributions from new investors Sanofi and Invus, alongside support from existing investors. Agomab Therapeutics plans to use the $89 million from its Series D financing…
Axena Health, Inc., a medical device company focused on female pelvic health, has announced the development of a machine learning model that could help clinicians create personalized treatments for female pelvic floor disorders. Researchers from Massachusetts General Hospital, the Massachusetts…
Hesperos, a leader in human biology recreation with its Human-on-a-Chip® platform, has made a significant advancement by developing a human induced pluripotent stem cell (iPSC)-derived model of peripheral myelination. This research, published in ACS Biomaterials, was conducted in collaboration with…
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical-stage gene editing company using its proprietary ARCUS® platform for advanced in vivo gene editing therapies, announced a poster presentation at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Congress, taking…
PharmaJet®, a company focused on enhancing injectable performance with its needle-free technology, has announced the results of an implementation study in Nigeria. This study evaluated the impact of administering the intradermal fractional inactivated poliovirus vaccine (fIPV) using the Tropis® ID…
Upfront Healthcare’s collaboration with Prisma Health, which has successfully engaged nearly one million patients, is featured in the latest issue of The Healthcare Administration Leadership & Management (HALM) Journal. Published by the American Association for Physician Leadership (AAPL), this journal…
BlueWind Medical, Ltd., a pioneer in implantable Tibial NeuroModulation (iTNM) and the creator of the Revi® System, has announced the presentation of new two-year data from its OASIS pivotal study. These findings were shared at the American Urogynecologic Society (AUGS)…
Simulations Plus, Inc. (Nasdaq: SLP), a top provider of biosimulation and performance solutions for the biopharma industry, has announced its financial results for the fourth quarter and fiscal year 2024, ending August 31, 2024. Fourth Quarter 2024 Financial Highlights (vs.…